Tradestie Institutional Equity Comparison Engine

ERAS vs BCAX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ERAS Overall Edge

ERAS Captures Institutional Edge (3โ€“0 Pillars ยท 4โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Erasca, Inc. Common Stock (ERAS) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ERAS trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus BCAX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ERAS sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro) against BCAX sits in BREAKDOWN (23rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ERAS N/M vs BCAX N/M Fwd P/E
Growth & Margin Winner ERAS
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner ERAS
1Y +494.9% vs -31.6% ยท 52W Pos 58% vs 8%
Options & Structure Winner ERAS
BREAKDOWN (6th %ile IV) vs BREAKDOWN (23rd %ile IV)
ERAS NASDAQ
Erasca, Inc. Common Stock
Pharmaceutical Preparations
$15.11
-3.51% 1D
Market Cap $5.5B
1M Return +12.85%
1Y Return +494.88%
Forward P/E N/M
Unified AI Score
37.5 / 100 SELL
Tech 20.0 Fund 47.0 Flow 70.0 Mom 64.0
BCAX NASDAQ
Bicara Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$9.75
-2.69% 1D
Market Cap $665.2M
1M Return -41.9%
1Y Return -31.63%
Forward P/E N/M
Unified AI Score
52.1 / 100 HOLD
Tech 58.0 Fund 66.0 Flow 68.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ERAS +494.88% BCAX -31.63% Spread: +526.51 pp (ERAS Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ERAS TTM Op. Margin: 0.0% BCAX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ERAS vs BCAX. Trailing 12-month operating profitability (ERAS 0.0% vs BCAX 0.0%) and valuation multiples (ERAS N/M vs BCAX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ERAS (4) vs BCAX (1)
Institutional Metric ERAS BCAX Criterion Row Winner
Market Capitalization Scale $5.5B $665.2M Larger Scale ERAS
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -48.7% -54.2% Higher ROE ERAS
52-Week Range Position Momentum 58% ($2โ€“$24) 8% ($8โ€“$31) Stronger Trend ERAS
Beta / 30D Volatility Risk Regime 2.30ฮฒ ยท 80% Vol 1.42ฮฒ ยท 184% Vol Lower Realized Risk ERAS
Unified Institutional Score Composite Signal 37.5 / 100 (SELL) 52.1 / 100 (HOLD) Higher Composite BCAX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ERAS vs BCAX Buy Guide
ERAS BREAKDOWN
87d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live ERAS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BCAX BREAKDOWN
93d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live BCAX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ERAS nor BCAX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.